Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 165

1.

Is multiple sclerosis a length-dependent central axonopathy? The case for therapeutic lag and the asynchronous progressive MS hypotheses.

Giovannoni G, Cutter G, Sormani MP, Belachew S, Hyde R, Koendgen H, Knappertz V, Tomic D, Leppert D, Herndon R, Wheeler-Kingshott CAM, Ciccarelli O, Selwood D, di Cantogno EV, Ben-Amor AF, Matthews P, Carassiti D, Baker D, Schmierer K.

Mult Scler Relat Disord. 2017 Feb;12:70-78. doi: 10.1016/j.msard.2017.01.007. Epub 2017 Jan 17. Review.

PMID:
28283111
2.

EHR is a Main Contributor to Physician Burnout.

Herndon RM.

J Miss State Med Assoc. 2016 Apr;57(4):124. No abstract available.

PMID:
27328477
3.

Dose conformation to the spine during palliative treatments using dynamic wedges.

Ormsby MA, Herndon RC, Kaczor JG.

Med Dosim. 2013 Summer;38(2):148-50. doi: 10.1016/j.meddos.2012.10.003. Epub 2012 Dec 21.

PMID:
23266164
4.

Differentiation of neuromyelitis optica from multiple sclerosis on spinal magnetic resonance imaging.

Lalan S, Khan M, Schlakman B, Penman A, Gatlin J, Herndon R.

Int J MS Care. 2012 Winter;14(4):209-14. doi: 10.7224/1537-2073-14.4.209.

5.

Gender effects on intramuscular interferon beta-1a in relapsing-remitting multiple sclerosis: analysis of 1406 patients.

Rudick RA, Kappos L, Kinkel R, Clanet M, Phillips JT, Herndon RM, Sandrock AW, Munschauer FE 3rd.

Mult Scler. 2011 Mar;17(3):353-60. doi: 10.1177/1352458510384605. Epub 2010 Oct 21.

PMID:
20965959
6.

Imbalance in multiple sclerosis: a result of slowed spinal somatosensory conduction.

Cameron MH, Horak FB, Herndon RR, Bourdette D.

Somatosens Mot Res. 2008;25(2):113-22. doi: 10.1080/08990220802131127.

7.
8.

Defining and diagnosing involuntary emotional expression disorder.

Cummings JL, Arciniegas DB, Brooks BR, Herndon RM, Lauterbach EC, Pioro EP, Robinson RG, Scharre DW, Schiffer RB, Weintraub D.

CNS Spectr. 2006 Jun;11(S6):1-7.

PMID:
16816786
9.

Multiple sclerosis mimics.

Herndon RM.

Adv Neurol. 2006;98:161-6. Review.

PMID:
16400833
10.

Psychiatric disorder in the children of antisocial parents.

Herndon RW, Iacono WG.

Psychol Med. 2005 Dec;35(12):1815-24.

PMID:
16300694
11.

Eight-year immunogenicity and safety of interferon beta-1a-Avonex treatment in patients with multiple sclerosis.

Herndon RM, Rudick RA, Munschauer FE 3rd, Mass MK, Salazar AM, Coats ME, Labutta R, Richert JR, Cohan SL, Genain C, Goodkin D, Toal M, Riester K.

Mult Scler. 2005 Aug;11(4):409-19.

PMID:
16042223
12.

Genetic and environmental influences on adolescents' perceptions of current family environment.

Herndon RW, McGue M, Krueger RF, Iacono WG.

Behav Genet. 2005 Jul;35(4):373-80.

PMID:
15971019
13.

Overview of spasticity management in multiple sclerosis. Evidence-based management strategies for spasticity treatment in multiple sclerosis.

Haselkorn JK, Balsdon Richer C, Fry Welch D, Herndon RM, Johnson B, Little JW, Miller JR, Rosenberg JH, Seidle ME; Multiple Sclerosis Council for Clinical Practice Guidelines.

J Spinal Cord Med. 2005;28(2):167-99. No abstract available.

PMID:
15889701
14.

Identifying and treating patients with suboptimal responses.

Cohen BA, Khan O, Jeffery DR, Bashir K, Rizvi SA, Fox EJ, Agius M, Bashir R, Collins TE, Herndon R, Kinkel P, Mikol DD, Picone MA, Rivera V, Tornatore C, Zwibel H.

Neurology. 2004 Dec 28;63(12 Suppl 6):S33-40. Review.

PMID:
15623669
15.

Review of mitoxantrone in the treatment of multiple sclerosis.

Jeffery DR, Herndon R.

Neurology. 2004 Dec 28;63(12 Suppl 6):S19-24. Review.

PMID:
15623665
16.

Geochemical imaging of flow near an artificial recharge facility, Orange County, California.

Clark JF, Hudson GB, Davisson ML, Woodside G, Herndon R.

Ground Water. 2004 Mar-Apr;42(2):167-74.

17.

Neural correlates of age-related declines in the formation and realization of delayed intentions.

West R, Herndon RW, Covell E.

Psychol Aging. 2003 Sep;18(3):461-73.

PMID:
14518808
18.

Effects of intention load and background context on prospective remembering: an event-related brain potential study.

West R, Wymbs N, Jakubek K, Herndon RW.

Psychophysiology. 2003 Mar;40(2):260-76.

PMID:
12820867
19.

Neural correlates of spatial term use.

Carlson LA, West R, Taylor HA, Herndon RW.

J Exp Psychol Hum Percept Perform. 2002 Dec;28(6):1391-408.

PMID:
12542134
20.

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. 1997.

Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Granger CV, Simon JH, Alam JJ, Simonian NA, Campion MK, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Pullicino PM, Scherokman BJ, Weistock-Guttman B, Whitham RH; Multiple Sclerosis Collaborative Research Group.

Neurology. 2001 Dec;57(12 Suppl 5):S25-30. No abstract available.

PMID:
11902591
21.
22.

Neural activity associated with the realization of a delayed intention.

West R, Herndon RW, Crewdson SJ.

Brain Res Cogn Brain Res. 2001 Aug;12(1):1-9.

PMID:
11489603
23.

Neuropsychological effects of interferon beta-1a in relapsing multiple sclerosis. Multiple Sclerosis Collaborative Research Group.

Fischer JS, Priore RL, Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Goodkin DE, Granger CV, Simon JH, Grafman JH, Lezak MD, O'Reilly Hovey KM, Perkins KK, Barilla-Clark D, Schacter M, Shucard DW, Davidson AL, Wende KE, Bourdette DN, Kooijmans-Coutinho MF.

Ann Neurol. 2000 Dec;48(6):885-92.

PMID:
11117545
24.

A longitudinal study of T1 hypointense lesions in relapsing MS: MSCRG trial of interferon beta-1a. Multiple Sclerosis Collaborative Research Group.

Simon JH, Lull J, Jacobs LD, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Sheeder J, Miller D, McCabe K, Serra A, Campion MK, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE 3rd.

Neurology. 2000 Jul 25;55(2):185-92.

PMID:
10908888
25.

Interferons in the treatment of multiple sclerosis: errors and misrepresentations.

Herndon RM.

Arch Neurol. 2000 Mar;57(3):426-7. No abstract available.

PMID:
10714676
26.

Selecting relapsing remitting multiple sclerosis patients for treatment: the case for early treatment.

Rudick RA, Goodman A, Herndon RM, Panitch HS.

J Neuroimmunol. 1999 Jul 1;98(1):22-8. Review. No abstract available.

PMID:
10426358
27.

A longitudinal study of brain atrophy in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

Simon JH, Jacobs LD, Campion MK, Rudick RA, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Simonian N, Lajaunie M, Miller DE, Wende K, Martens-Davidson A, Kinkel RP, Munschauer FE 3rd, Brownscheidle CM.

Neurology. 1999 Jul 13;53(1):139-48.

PMID:
10408550
28.

Cerebrospinal fluid abnormalities in a phase III trial of Avonex (IFNbeta-1a) for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

Rudick RA, Cookfair DL, Simonian NA, Ransohoff RM, Richert JR, Jacobs LD, Herndon RM, Salazar AM, Fischer JS, Granger CV, Goodkin DE, Simon JH, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munchsauer FE, O'Reilly K, Priore RL, Whitham RH, et al.

J Neuroimmunol. 1999 Jan 1;93(1-2):8-14.

PMID:
10378864
29.

Is Alexander's disease a nosologic entity or a common pathologic pattern of diverse etiology?

Herndon RM.

J Child Neurol. 1999 May;14(5):275-6. Review. No abstract available.

PMID:
10342592
30.

Interferon beta treatment for multiple sclerosis.

Herndon RM.

Lancet. 1999 Feb 6;353(9151):494-5; author reply 497-8. No abstract available.

PMID:
9989739
31.

Comparing the ability of various compositive outcomes to discriminate treatment effects in MS clinical trials. The Multiple Sclerosis Collaborative Research Group (MSCRG).

Goodkin DE, Priore RL, Wende KE, Campion M, Bourdette DN, Herndon RM, Fischer JS, Jacobs LD, Cookfair DL, Rudick RA, Richert JR, Salazar AM, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Whitham RH, et al.

Mult Scler. 1998 Dec;4(6):480-6.

PMID:
9987756
32.

Interferons should be used to treat most patients with MS.

Herndon RM, Jacobs L.

Arch Neurol. 1998 Dec;55(12):1581-3. No abstract available.

PMID:
9865806
33.

Quantification of white matter and gray matter volumes from three-dimensional magnetic resonance volume studies using fuzzy classifiers.

Herndon RC, Lancaster JL, Giedd JN, Fox PT.

J Magn Reson Imaging. 1998 Sep-Oct;8(5):1097-105.

PMID:
9786148
34.

Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis. Multiple Sclerosis Collaborative Research Group (MSCRG)

Rudick RA, Simonian NA, Alam JA, Campion M, Scaramucci JO, Jones W, Coats ME, Goodkin DE, Weinstock-Guttman B, Herndon RM, Mass MK, Richert JR, Salazar AM, Munschauer FE 3rd, Cookfair DL, Simon JH, Jacobs LD.

Neurology. 1998 May;50(5):1266-72.

PMID:
9595973
35.

Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group.

Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Alam JJ, Fischer JS, Goodkin DE, Granger CV, Lajaunie M, Martens-Davidson AL, Meyer M, Sheeder J, Choi K, Scherzinger AL, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Whitham RH, et al.

Ann Neurol. 1998 Jan;43(1):79-87.

PMID:
9450771
36.

Impact of interferon beta-1a on neurologic disability in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG).

Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, Richert JR, Salazar AM, Fischer JS, Granger CV, Simon JH, Alam JJ, Simonian NA, Campion MK, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE, Priore RL, Whitham RH, et al.

Neurology. 1997 Aug;49(2):358-63.

PMID:
9270562
37.

Magnetic resonance imaging demonstrates incomplete myelination in 18q- syndrome: evidence for myelin basic protein haploinsufficiency.

Gay CT, Hardies LJ, Rauch RA, Lancaster JL, Plaetke R, DuPont BR, Cody JD, Cornell JE, Herndon RC, Ghidoni PD, Schiff JM, Kaye CI, Leach RJ, Fox PT.

Am J Med Genet. 1997 Jul 25;74(4):422-31.

PMID:
9259379
38.

Quantification of white matter and gray matter volumes from T1 parametric images using fuzzy classifiers.

Herndon RC, Lancaster JL, Toga AW, Fox PT.

J Magn Reson Imaging. 1996 May-Jun;6(3):425-35.

PMID:
8724407
39.

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, Salazar AM, Fischer JS, Goodkin DE, Granger CV, Simon JH, Alam JJ, Bartoszak DM, Bourdette DN, Braiman J, Brownscheidle CM, Coats ME, Cohan SL, Dougherty DS, Kinkel RP, Mass MK, Munschauer FE 3rd, Priore RL, Pullicino PM, Scherokman BJ, Whitham RH, et al.

Ann Neurol. 1996 Mar;39(3):285-94. Erratum in: Ann Neurol 1996 Sep;40(3):480.

PMID:
8602746
40.

Herpesviruses in multiple sclerosis.

Herndon RM.

Arch Neurol. 1996 Feb;53(2):123-4. No abstract available.

PMID:
8639060
41.

Evasion of immunologic defenses and emerging viral threats.

Herndon RM.

Arch Neurol. 1996 Jan;53(1):23-7. Review.

PMID:
8599554
42.
43.

Neurology should not become a consulting specialty.

Herndon RM.

Arch Neurol. 1995 Feb;52(2):205-6. No abstract available.

PMID:
7848134
44.

Advances in specific therapy for multiple sclerosis.

Jacobs L, Goodkin DE, Rudick RA, Herndon R.

Curr Opin Neurol. 1994 Jun;7(3):250-4. Review.

PMID:
8081519
45.

Morphological correlates of altered neuronal activity in organotypic cerebellar cultures chronically exposed to anti-GABA agents.

Seil FJ, Drake-Baumann R, Leiman AL, Herndon RM, Tiekotter KL.

Brain Res Dev Brain Res. 1994 Jan 14;77(1):123-32.

PMID:
7907533
46.

Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: final report of the Northeast Cooperative Multiple Sclerosis Treatment Group.

Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, LaPierre Y, Herndon R, Lehrich JR, Hauser SL, Turel A, et al.

Neurology. 1993 May;43(5):910-8.

PMID:
8388090
47.

Cytosine arabinoside effects in mouse cerebellar cultures in the presence of astrocytes.

Seil FJ, Drake-Baumann R, Herndon RM, Leiman AL.

Neuroscience. 1992 Nov;51(1):149-58.

PMID:
1465178
48.

Multiple sclerosis masquerading as a mass lesion.

Giang DW, Poduri KR, Eskin TA, Ketonen LM, Friedman PA, Wang DD, Herndon RM.

Neuroradiology. 1992;34(2):150-4.

PMID:
1603315
49.

Reorganization of organotypic cultures of mouse cerebellum exposed to cytosine arabinoside: a timed ultrastructural study.

Seil FJ, Herndon RM, Tiekotter KL, Blank NK.

J Comp Neurol. 1991 Nov 8;313(2):193-212.

PMID:
1765580

Supplemental Content

Loading ...
Support Center